Forum Member and Staff Biographies
JOSHUA LEDERBERG, Ph.D., is University Professor of Molecular Genetics and Informatics at The Rockefeller University, New York, N.Y. His lifelong research, for which he received the Nobel Prize in 1958, has been in genetic structure and function in microorganisms. He has a keen interest in international health and was cochair of a previous Institute of Medicine Committee on Emerging Microbial Threats to Health (1990–1992). He has been a member of the National Academy of Sciences since 1957 and is a charter member of the Institute of Medicine. Dr. Lederberg is the chair of the Forum on Emerging Infections.
VINCENT AHONKHAI, M.D., is Vice President and Director at SmithKline Beecham Pharmaceuticals and is responsible for Clinical R&D and Medical Affairs in Anti-Infectives and Biologicals, North America. He has held this position since 1995 overseeing a product portfolio that includes antibiotics, antivirals, and vaccines. After completing medical school and internships in Nigeria, Dr. Ahonkhai obtained additional training in pediatric residency, followed by a fellowship in infectious diseases in adults and pediatrics at the State University of New York-Downstate Medical Center, Brooklyn, N.Y., from 1975 to 1980. He then joined the faculty as Assistant Professor, Department of Pediatrics. In 1982, Dr. Ahonkhai started his pharmaceutical industry career as Associate Director, Infectious Diseases, at Merck, where he rose to director level. Subsequently, he moved to the Robert Wood Johnson Pharmaceutical Research Institute, where he served first as Head of Infectious Diseases and later as Executive Director, Dermatology and Wound Healing. Dr. Ahonkhai is board-certified in pediatrics and is a long-standing member and fellow of several professional organizations including the American Medical Association, National Medical Association, American Society for Microbiology, Infectious Diseases Society of
America (fellow), Pediatric Infectious Diseases Society, and American Academy of Pharmaceutical Physicians (Vice President, Membership Development Committee, and board member).
STEVEN J. BRICKNER, Ph.D., is Manager of Medicinal Chemistry at Pfizer Central Research, where he leads a team of medicinal chemists that is focused on the discovery and development of new antibacterial agents designed to meet the growing problems with resistance. He has more than 15 years of pharmaceutical industrial research experience, all directed at the discovery of novel antibiotics. Before joining Pfizer, he led a team that discovered and developed linezolid, the first oxazolidinone to undergo phase III clinical evaluation. Dr. Brickner is recognized as a world expert on this new class of antibacterial agents.
NANCY CARTER-FOSTER, M.S.T.M., is Director of the U.S. Department of State's Emerging Infectious Diseases Program and is responsible for heading the department's policy coordination on infectious diseases and human immunodeficiency virus-AIDS issues and integrating international health issues with economic and national security implications into U.S. foreign policy. She coordinates with the State Department's 250 embassies, missions, and agencies to address global infectious disease priorities and to effect a unified United States' government response. Ms. Carter-Foster has been a foreign affairs advisor to the then Majority Whip of the U.S. House of Representatives, Congressman William H. Gray, and was the U.S. chief negotiator on international population issues, and the roles and status of women and international health issues which lead to the United Nation's (UN) World Conference on Population and Development, the UN Conference on Environment and Development (UNCED), and a myriad of other bilateral and multilateral fora. She also has a background in environmental systems management, ocean affairs, law of the sea, and coastal zone development.
GAIL H. CASSELL, Ph.D., is Vice President, Infectious Diseases, Drug Discovery Research, and Clinical Investigation at Eli Lilly & Company. Previously, she was the Charles H. McCauley Professor and (since 1987) Chair, Department of Microbiology, University of Alabama Schools of Medicine and Dentistry at Birmingham, a department which ranked first in research funding from the National Institutes of Health since 1989 under her leadership. She is a member of the Director's Advisory Committee of the National Centers for Disease Control and Prevention, Dr, Cassell is past president of the American Society for Microbiology, a former member of the National Institutes of Health Director's Advisory Committee, and a former member of the Advisory Council of the National Institute of Allergy and Infectious Diseases. She also has served as an adviser on infectious diseases and indirect costs of research to the White House Office on Science and Technology and was previously chair of the Board of Scientific Councilors of the Center for Infectious Diseases Centers for the National Centers for Disease Control and Prevention. Dr. Cassell served 8 years on the Bacte
riology-Mycology 2 Study Section and served as its chair for 3 years. She serves on the editorial boards of several prestigious scientific journals and has authored over 250 articles and book chapters. She has been intimately involved in the establishment of science policy and legislation related to biomedical research and public health. Dr. Cassell has received several national and international awards and an honorary degree for her research on infectious diseases.
GORDON DeFRIESE, Ph.D., is Professor of Social Medicine, Epidemiology, and Health Policy and Administration and Director of the Cecil G. Sheps Center for Health Services Research at the University of North Carolina at Chapel Hill. He received his Ph.D. from the University of Kentucky College of Medicine. Some of his research interests are in the areas of health promotion and disease prevention, medical sociology, primary health care, rural health care, cost-benefit analysis, and cost-effectiveness. He is a member of the Global Advisory Group on Health Systems Research of the World Health Organization in Geneva, past president of the Association for Health Services Research and the Foundation for Health Services Research, and a fellow of the New York Academy of Medicine. He is founder of the Partnership for Prevention, a coalition of private-sector business and industry organizations, voluntary health organizations, and state and federal public health agencies based in Washington, D.C., that have joined together to work toward the elevation of disease prevention among the nation's health policy priorities.
RENU GUPTA, M.D., is Vice President, Medical Safety and Therapeutics of Corarice. As an infectious disease specialist, Dr. Gupta is active in a number of professional societies, including the Infectious Diseases Society of America and the American Society for Microbiology, where she is a member of the committee on education. She is a frequent presenter at the Interscience Conference on Antimicrobial Agents and Chemotherapy and other major infectious disease congresses and has been published in leading infectious disease periodicals such as Journal of Virology, the Journal of Infectious Diseases, and Antimicrobial Agents and Chemotherapy. Dr. Gupta received her M.B. and Ch.B. from the University of Zambia. Subsequently, she served as Chief Resident in Pediatrics at the Albert Einstein Medical Center and as a Fellow in Infectious Diseases at the Children's Hospital of Philadelphia. She was also Postdoctoral Fellow in Microbiology at the University of Pennsylvania and the Wistar Institute of Anatomy and Biology, where she conducted research on the pathogenesis of infectious diseases. From 1989 to mid-1998, Dr. Gupta was with Bristol-Myers Squibb Company, where she directed clinical research as well as strategic planning for the Infectious Diseases and Immunology Division. For the past several years, her work has focused on a better understanding of the problem of emerging infections. Dr. Gupta currently chairs the steering committee for the SENTRY Antimicrobial Surveillance Program.
MARGARET A. HAMBURG, M.D., is the Assistant Secretary for Planning and Evaluation at the U.S. Department of Health and Human Services. Previously, she was the Health Commissioner for the City of New York. She holds appointments as Adjunct Assistant Professor of Medicine at the Cornell University Medical Center and Assistant Professor of Public Health at the Columbia University School of Public Health. In her previous position as special assistant to National Institute of Allergy and Infectious Diseases Director Anthony Fauci, M.D., she played a major role in research administration and policy development in the area of infectious diseases. She serves on the Board of Scientific Counselors of the Center for Infectious Diseases at the Centers for Disease Control and Prevention. She received her M.D. from Harvard Medical School and completed her internship and residency in internal medicine at New York Hospital/Cornell Medical Center and is board-certified in internal medicine. Dr. Hamburg is the author of many scientific articles and the recipient of numerous awards for distinguished public service.
DIETER HINZEN, biographical information is not available.
JAMES M. HUGHES, M.D., is Assistant Surgeon General and Director of the National Center for Infectious Diseases (NCID) at the Centers for Disease Control and Prevention (CDC). He was named Deputy Director of NCID in 1988 and became Director of the Center in 1992. He joined CDC as an Epidemic Intelligence Service Officer in 1973, during which time he focused on the epidemiology of foodborne, waterborne, and other diarrheal diseases. Dr. Hughes received his M.D. in 1971 from Stanford University. He is board-certified in internal medicine, infectious diseases, and preventive medicine. He is a Fellow of the American College of Physicians and the Infectious Diseases Society of America.
J. STANLEY HULL is Vice President of Marketing for Gastrointestinal and Anti-Infectives Research at Glaxo Wellcome. He is responsible for developing revenue forecasts and expense budgets and for reviewing marketing plans for these therapeutic areas. More of his attention is given to pipeline products to ensure that these products are developed to meet customer needs. Before taking his current position, he served as Vice President of Marketing for Glaxo Pharmaceuticals, where he was involved in the commercial development of products in the gastrointestinal, antibacterial, anesthesia, and antiviral therapeutic areas. He has served in various sales and marketing positions in the pharmaceutical industry since he began his career in 1978. He holds a B.S. degree in business administration and economics from the University of North Carolina at Greensboro.
SAMUEL L. KATZ, M.D., is Chairman of the Board of the Burroughs Wellcome Fund and Wilburt C. Davison Professor and chairman emeritus of pediatrics at Duke University Medical Center. He has concentrated his research on infectious diseases, focusing primarily on vaccine research and development,
having developed the attenuated measles virus vaccine with Nobel Laureate John F. Enders which is now used throughout the world. He is a past-chair and member of the Public Policy Council of the infectious Diseases Society of America. Dr. Katz has served on a number of scientific advisory committees and is the recipient of many prestigious awards and honorary fellowships in international organizations. Dr. Katz received his M.D. from Harvard Medical School. After his medical internship at Beth israel Hospital, he completed his pediatrics residency training at the Massachusetts General Hospital and the Boston Children's Hospital. Then he became a staff member at Children's Hospital, working with Nobel Laureate John F. Enders. He has chaired the Committee on Infectious Diseases of the American Academy of Pediatrics (the Redbook Committee), the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention, the Vaccine Priorities Study of the Institute of Medicine (IOM), and several World Health Organization (WHO) and Children's Vaccine Initiative panels on vaccines and human immunodeficiency virus infections. He is a member of many scientific advisory committees and boards including those of the National Institutes of Health, IOM, and WHO. Dr. Katz's published studies include more than 100 original scientific articles, 60 chapters in textbooks, and many abstracts, editorials, and reviews. He is the co-editor of a textbook on pediatric infectious diseases and has given more than 70 named lectures in the United States and abroad.
KENNETH W. KIZER, M.D., M.P.H., is President and Chief Executive Officer of the National Quality Forum. Formerly, he served as the Under Secretary for Health at the U.S. Department of Veterans Affairs, Veterans Health Administration. As the Under Secretary for Health, he was the highest ranking physician in the federal government and the chief executive officer of the health care system in the U.S. His professional experience before joining the U.S. Department of Veterans Affairs includes serving on the boards of Health Systems International, Inc., and the California Wellness Foundation. He is board-certified in five medical specialties and has authored over 300 chapters, book chapters, and other reports in the medical literature. Dr. Kizer has held senior academic positions at the University of California, Davis, and continues as an Adjunct Professor of Public Policy at the University of Southern California. He is a fellow of the American College of Emergency Physicians, the American College of Occupational and Environmental Medicine, the Royal Society of Health, and the Royal Society of Medicine. Dr. Kizer is an honors graduate of Stanford University and the University of California, Los Angeles.
WILLIAM KOHLBRENNER, Ph.D., is Director of Antiviral Research in the Pharmaceutical Products Division at Abbott Laboratories in North Chicago, Ill. He received his Ph.D. from the State University of New York and completed postdoctoral training at the Molecular Biology Institute at the University of California, Los Angeles. Dr. Kohlbrenner has contributed to a number of industrial research programs focused on the discovery of novel antibacterial and antiviral
agents. He has coauthored many articles on the fundamental aspects of various microbial therapeutic targets and the molecular basis of drug action. He has a strong interest in the development of resistance to antimicrobial agents and in devising appropriate therapeutic strategies for effectively dealing with drug resistance problems.
JOHN R. LaMONTAGNE, Ph.D., is Deputy Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health. Previously, Dr. LaMontagne was Director of the Division of Microbiology and Infectious Diseases at NIAID. Within NIA1D, he has also served as Director of the AIDS Program and Influenza Program Officer. Dr. LaMontagne received his Ph.D. in microbiology from Tulane University and did a postdoctoral fellowship in the laboratory of Julius Youngner at the University of Pittsburgh. There he devoted his efforts to the characterization of vital products produced by cells persistently infected with Newcastle disease virus. His interests are in vaccine research and development.
CARLOS LOPEZ, Ph.D., is Research Fellow, Research Acquisitions, Eli Lilly Research Laboratories. He received his Ph.D. from the University of Minnesota in 1970. Dr. Lopez was awarded the NTRDA postdoctoral fellowship. After his fellowship he was appointed Assistant Professor of Pathology at the University of Minnesota, where he did his research on cytomegalovirus infections in renal transplant recipients and the consequences of those infections. He was also appointed assistant member and head of the Laboratory of Herpesvirus Infections at the Sloan Kettering Institute for Cancer Research, where his research focused on herpes virus infections and the mechanisms involved. Dr. Lopez's laboratory contributed to the immunological analysis of the earliest AIDS patients at the beginning of the AIDS epidemic in New York. He is coauthor of one of the seminal publications on this disease, as well as many scientific papers and is co-editor of six books. Dr. Lopez has held consultantships with numerous organizations including the National Institutes of Health, the U.S. Department of Veterans Affairs, and the American Cancer Society.
STEPHEN S. MORSE, Ph.D., is a Program Manager in the Defense Sciences Office at the Defense Advanced Research Projects Agency (DARPA). Dr. Morse is also Assistant Professor of Virology at The Rockefeller University, where he has been since 1985. In July 1996, he joined the faculty of Columbia University School of Public Health, Division of Epidemiology. Dr. Morse is a virologist and immunologist with research interests in viral effects on Tlymphocyte development and function, viral zoonoses, and methods for studying viral evolution. He was principal organizer and Chair of the 1989 Conference on Emerging Viruses at the National Institutes of Health, and is a member of the Institute of Medicine Committee on Emerging Infections (1990–1992), a current member of the Institute of Medicine Committee on Xenograft Transplantation, and Chair of the Microbiology Section of the New York Academy of Sciences.
He is Chair of ProMed (Program for Monitoring Emerging Infections), formed in January 1993, to encourage development of initiatives for anticipating and responding to worldwide emerging infections.
SOLOMON MOWSHOWITZ, Ph.D., is President of Diligen, a New York City biotechnology consultancy. Diligen performs due diligence in biotechnology, as well as technical consulting, grant writing, technology transfer, and opportunity assessment. Dr. Mowshowitz received his Ph.D. in biochemistry from the Albert Einstein College of Medicine in 1970, and is licensed to practice before the United States Patent and Trademark Office. He taught microbiology and infectious diseases at the Mount Sinai School of Medicine in New York from 1970 to 1984. Beginning in 1985, he held senior positions at a series of commercial biotechnology firms, most recently having served as Vice President, Research and Development at AMBI, Inc. until 1998. Dr. Mowshowitz's primary expertise is in the areas of infectious diseases, cancer therapeutics, DNAbased diagnostics (including forensics), and patent law.
STUART L. NIGHTINGALE, M.D., is Associate Commissioner for Health Affairs, U.S. Food and Drug Administration, U.S. Department of Health and Human Services. Dr. Nightingale earned his M.D. from New York University School of Medicine and then served as intern (mixed medicine) at Montefiore Hospital and Medical Center in New York, as a resident in internal medicine (including 1 year as a fellow in adolescent medicine) at Montefiore Hospital and Medical Center, and as a resident in anatomical pathology at New York University School of Medicine. He is board-certified in internal medicine, a fellow of the American College of Physicians, and a member of the American Medical Association and the American Public Health Association. Dr. Nightingale heads the Office of Health Affairs of the U.S. Food and Drug Administration (FDA), after prior appointments at several universities, the National Institute of Drug Abuse, and the Executive Office of the President of the United States. Dr. Nightingale has published numerous articles on the impact of federal and state legislation and regulations on medical practice, health fraud, protection of human subjects of research, policy formulation and drug regulation, safety and efficacy determinations and the health effects of FDA-regulated products, and drug abuse prevention, He has received the Award for Distinguished Service, Special Action Office for Drug Abuse Prevention, Executive Office of the President, the Public Health Service Superior Service Award, and FDA's Award of Merit on three occasions. He received the Achievement Award from the American Association of Physicians for Human Rights and received the Presidential Meritorious Executive Rank Award.
MICHAEL T. OSTERHOLM, Ph.D., M.P.H., is the Chairman and Chief Executive Officer of the Infection Control Advisory Network. Previously, Dr. Osterholm was the State Epidemiologist and Chief of the Acute Disease Epidemiology Section for the Minnesota Department of Health. He is also an Adjunct Professor of the Division of Epidemiology, School of Public Health, at the Uni-
versity of Minnesota. He has received numerous research awards from the National Institute of Allergy and Infectious Diseases and the Centers for Disease Control and Prevention (CDC). He serves as Principal Investigator for the CDC sponsored Emerging Infections Program in Minnesota. He has published more than 140 articles on various emerging infectious disease problems. He is past President of the Council of State and Territorial Epidemiologists and chairs its Committee on Public Health, and is a member of the Board of Scientific Counselors, National Centers for Infectious Diseases, CDC, and a member of the National Advisory Committee on Microbial Criteria for Foods, U.S. Department of Agriculture. He recently served as a member of the Committee on the Department of Defense Persian Gulf War Syndrome Comprehensive Clinical Evaluation Program of the Institute of Medicine.
DAVID M. SHLAES, M.D., Ph.D., is Vice President for Infectious Diseases Research at Wyeth-Ayerst Research. Before joining Wyeth-Ayerst, Dr. Shlaes was Professor of Medicine at the Case Western Reserve University School of Medicine and Chief of the Infectious Diseases Section and the Clinical Microbiology Unit at the Veterans Affairs Medical Center in Cleveland, Ohio. He has served as a grant reviewer for the U.S. Department of Veterans Affairs Infectious Diseases Merit Review Board and the National Institutes of Health Special Study Section on Biology of Mycobacteria. He has published widely in peerreviewed journals, and his interest is in antimicrobial agents and chemotherapy and antibiotic resistance.
JOHN D. SIEGFRIED, M.D., is Associate Vice President for Medical, Regulatory and Scientific Affairs at the Pharmaceutical Research and Manufacturers of America. Dr. Siegfried is a pediatrician with 25 years in clinical practice and for the past decade has been involved with pharmaceutical research and development in the medical and regulatory affairs section of the R.W. Johnson Pharmaceutical Research Institute. He began his career with the U.S. Public Health Service as Medical Officer on the Rosebud and the Redlake lndian Reservations and completed his active pediatric practice as Chief of Pediatrics and Chief of the Medical Staff at the Al Hada Hospital and Rehabilitation Center in Taif, Saudi Arabia. As a volunteer physician, Dr. Siegfried regularly staffs the Whitman Walker AIDS Clinic in the District of Columbia as well as its clinic for sexually transmitted diseases.
P. FREDERICK SPARLING, M.D., is a J. Herbert Bate Professor of Medicine, Microbiology and Immunology at the University of North Carolina (UNC) at Chapel Hill and is Director of the North Carolina Sexually Transmitted Infections Research Center. Previously, he served as Chair of the Department of Medicine and Chair of the Department of Microbiology and Immunology at UNC. He was president of the Infectious Disease Society of American in 1996–1997. He was also a member of the Institute of Medicine's Committee on Microbial Threats to Health (1991–1992). Dr. Sparling's laboratory research is in
the molecular biology of bacterial outer membrane proteins involved in pathogenesis, with a major emphasis on gonococci and meningococci. His current studies focus on the biochemistry and genetics of iron-scavenging mechanisms used by gonococci and meningococci and the structure and function of the gonococcal prion proteins. He is pursuing the goal of a vaccine for gonorrhea.
JONATHAN R. DAVIS, Ph.D., is currently a Senior Program Officer at the Institute of Medicine (IOM). His primary charge is as Study Director of IOM's Forum on Emerging Infections and the Roundtable on Research and Development of Drugs, Biologics, and Medical Devices. Dr. Davis was formerly the Science Officer for the Emerging Infectious Diseases and HIV/AIDS Program in the U.S. Department of State's Bureau of Oceans and International Environmental and Scientific Affairs. Prior to his work at the State Department, Dr. Davis was an Assistant Professor of Medicine and Head of the Malaria Laboratory at the University of Maryland School of Medicine where he was the principal and co-principal investigator on grants investigating the fundamental biology of malaria transmission, and on the development and testing of candidate malaria vaccines in human volunteers. Dr. Davis has a M.S. in Medical Entomology and Parasitology from Clemson University, and a Ph.D. in Immunology and Infectious Diseases from The Johns Hopkins University School of Hygiene and Public Health. Dr. Davis is an ad hoc reviewer for several professional scientific journals, and currently holds adjunct faculty appointments at The Johns Hopkins University School of Hygiene and Public Health, the University of Maryland School of Medicine, and the Uniformed Services University School of the Health Sciences.
POLLY F. HARRISON, Ph.D., is the founder and head of the Alliance for Microbicide Development, an investigator-led consortium of small biopharmaceutical companies, scientists, and advocates whose objectives are to advocate for microbicide development and educate the public and policy communities about its importance; track and communicate product progress through the research and development pipeline; foster building of a funding base to support combination and comparative studies; improve the efficiency of preclinical development processes; and explore, research, and inform interested parties about critical topics. Before she founded the Alliance, Dr. Harrison worked for two decades in the developing world as a medical anthropologist and policy analyst in a range of activities related to women's health. She then went on to serve as Senior Program Officer at the Institute of Medicine (IOM) and as Director of its Division of International Health. In the former position, she established and directed the IOM's Forum on Emerging Infections. Her undergraduate and graduate degrees are from Mount Holyoke College and the Catholic University of America, respectively. She is a governing counselor of the American Public Health Association
and a fellow of the American Anthropological Association and serves as an adjunct professor at The Johns Hopkins University School for Advanced International Studies. Her personal research interests continue to center on ways to motivate the participation of the biopharmaceutical industry in developing products that have low perceived profitability but high value for worldwide public health.
VIVIAN P. NOLAN, M.A., is the Research Associate for the Forum on Emerging Infections and for the Roundtable on Research and Development of Drugs, Biologics, and Medical Devices. Before joining the Institute of Medicine (IOM), Ms. Nolan was a Science Assistant in the Division of Environmental Biology at the National Science Foundation (NSF) where she worked on grants administration, research projects, and policy analyses on environmental and conservation biology issues. Ms. Nolan is a recipient of a NSF Directors Award for the policy-oriented, interdisciplinary Water and Watersheds collaborative NSF-U.S. Environmental Protection Agency grants program. Ms. Nolan is pursuing her doctorate in environmental science and public policy from George Mason University. Her graduate work has included research and policy analysis on issues ranging from environmental, biodiversity conservation, sustainable development, human health, and emerging and reemerging infectious diseases. In August 1998, she participated in an educational program in Kenya that studied the relationship between ecological degradation and emerging infectious diseases. Ms. Nolan was awarded an M.A. in science, technology and public policy in 1994 from the George Washington University, and in 1987 she simultaneously earned two bachelor's degrees in international studies and Latin American studies.
NICOLE AMADO, was the Project Assistant for the Institute of Medicine's (IOM) Forum on Emerging Infections and for the IOM Roundtable on Research and Development of Drugs, Biologics, and Medical Devices. Ms. Amado was formerly a Project Coordinator for the Cystic Fibrosis Foundation. Prior to her work at the Cystic Fibrosis Foundation, she was a Panel Assistant with the Chemical Manufacturers Association. Ms. Amado has considerable experience in project organization, research and analysis, and administrative problem solving. Ms. Amado earned a bachelor's degree in biology from the University of Louisville in 1994.
CHRISTINA THACKER joined the Institute of Medicine's (IOM) Health Sciences Policy Division in January 1997. She worked as the Research Assistant on the IOM's Forum on Emerging Infections and the Roundtable on Research and Development of Drugs, Biologics, and Medical Devices. Before joining the IOM, Ms. Thacker worked on policy issues pertaining to legal immigration and advocated on behalf of immigrants and refugees in the United States. She received a bachelor's degree in history and German from Wake Forest University. Ms. Thacker is currently pursuing a law degree from the University of Michigan at Ann Arbor.
GRETCHEN KIDDER, is a Research Associate for the Alliance for Microbicide Development in Silver Spring, MD. She graduated from the University of Vermont with a B.S. in biology in 1991. Upon graduation, Ms. Kidder moved to Seattle, Washington, to begin graduate studies in epidemiology and work and research in the chlamydia laboratory at the University of Washington. She went on to research a primate model being developed to test microbicidal products. Ms. Kidder worked as a Research Assistant for the IOM's Forum on Emerging Infectious Diseases and the Roundtable on the Development of Drugs, Medical Devices, and Biologics at the Institute of Medicine until 1998.
There was a problem loading page 114.